A Phase 3 Randomized Double Blind Placebo Controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) and Open Label Extension

Trial Profile

A Phase 3 Randomized Double Blind Placebo Controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) and Open Label Extension

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Ataluren (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Therapeutic Use
  • Sponsors PTC Therapeutics
  • Most Recent Events

    • 11 Jul 2017 Status changed from not yet recruiting to recruiting.
    • 05 Jun 2017 Status changed from planning to not yet recruiting.
    • 24 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top